IWA
CRL icon

Intercontinental Wealth Advisors’s Charles River Laboratories CRL Stock Holding History

Intercontinental Wealth Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$521K Buy
2,478
+95
+4% +$18.9K 0.12% 179
2023
Q1 		$481K Sell
2,383
-86
-3% -$19.5K 0.12% 200
2022
Q4 		$538K Hold
2,469
– – 0.16% 151
2022
Q3 		$486K Buy
2,469
+46
+2% +$9.93K 0.15% 152
2022
Q2 		$518K Sell
2,423
-41
-2% -$10K 0.14% 157
2022
Q1 		$700K Buy
2,464
+18
+0.7% +$5.55K 0.16% 131
2021
Q4 		$922K Buy
2,446
+988
+68% +$384K 0.19% 104
2021
Q3 		$602K Sell
1,458
-128
-8% -$53.2K 0.14% 145
2021
Q2 		$587K Buy
1,586
+243
+18% +$81.1K 0.12% 161
2021
Q1 		$389K Buy
1,343
+197
+17% +$54.8K 0.08% 186
2020
Q4 		$286K Buy
+1,146
New +$273K 0.07% 204

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Intercontinental Wealth Advisors's CRL Position: Q2 2023 in Review

Intercontinental Wealth Advisors increased its Charles River Laboratories (CRL) stake by 4% in Q2 2023, buying an estimated $18.9K and bringing the position to 2,478 shares worth $521K. The position accounts for 0.12% of the portfolio, ranked #179.

Intercontinental Wealth Advisors first reported a position in CRL in Q4 2020 and has held it in 11 quarters since. The position peaked at $922K in Q4 2021. 612 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

  • Intercontinental Wealth Advisors held 2,478 shares of Charles River Laboratories worth $521K as of Q2 2023.
  • Intercontinental Wealth Advisors bought 95 Charles River Laboratories shares in Q2 2023, an estimated $18.9K.
  • Charles River Laboratories made up 0.12% of Intercontinental Wealth Advisors's portfolio in Q2 2023, its #179 holding.
  • Intercontinental Wealth Advisors first reported a position in Charles River Laboratories in Q4 2020 and has held it in 11 quarters since.
  • Intercontinental Wealth Advisors's Charles River Laboratories position peaked at $922K in Q4 2021.
  • 612 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on Intercontinental Wealth Advisors's 13F filing for Q2 2023, filed 21 Jul 2023.